Monopar Therapeutics Inc.
monopartx.comWhat Do They Do?
Develops an investigational medicine for people with Wilson disease and radiopharmaceuticals for imaging and treating advanced cancers.
10-K for FY2025, filed Mar 27, 2026Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we,” “us,” and “our” and similar terms mean Monopar Therapeutics Inc. and its…View ↗
ALXN1840 (tiomolybdate choline) is an investigational once-daily, orally-administered drug candidate in development for the treatment of…View ↗
MNPR-101 is our proprietary humanized monoclonal antibody that we are developing for advanced solid tumors expressing uPAR. This novel…View ↗
Following encouraging Phase 1 clinical data regarding tumor uptake, biodistribution, and safety of MNPR-101-Zr, we decided to evaluate the…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 27, 2026
How Are They Changing?
Added Wilson disease development
The older report focused on cancer treatments; the latest report also describes development of a treatment for Wilson disease.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 27, 2026We are a clinical stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve quality…View ↗
Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we,” “us,” and “our” and similar terms mean Monopar Therapeutics Inc. and its…View ↗
Who Do They Compete With?
Competes with Bausch Health, Meda Pharmaceuticals, Viatris, Orphalan, Eton Pharmaceuticals, Ultragenyx Pharmaceutical, Vivet Therapeutics, Novartis, Bayer, Bristol Myers Squibb, Eli Lilly, Actinium Pharmaceuticals, Johnson & Johnson, Telix Pharmaceuticals, Lantheus Holdings, AstraZeneca, Genentech, and CuraSight
10-K for FY2025, filed Mar 27, 2026While there is no cure for Wilson disease, the FDA has approved several therapeutic agents for the treatment of Wilson disease. Treatment…View ↗
Loading...
